CHE Quote, Financials, Valuation and Earnings

Amedisys has a net margin of 11.09% compared to Chemed's net margin of 10.26%. Chemed's return on equity of 26.04% beat Amedisys's return on equity of 7.55%.

Chemed has a consensus price target of $646.67, signalling upside risk potential of 43.29%. On the other hand Amedisys has an analysts' consensus of $97.38 which suggests that it could fall by -0.09%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

Chemed has a beta of 0.496, which suggesting that the stock is 50.426% less volatile than S&P 500. In comparison Amedisys has a beta of 0.943, suggesting its less volatile than the S&P 500 by 5.651%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.44%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $646.9M, which are larger than Amedisys quarterly revenues of $594.8M. Chemed's net income of $71.8M is higher than Amedisys's net income of $61M. Notably, Chemed's price-to-earnings ratio is 21.98x while Amedisys's PE ratio is 35.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 2.73x versus 1.36x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst has a net margin of 11.09% compared to Chemed's net margin of -29.9%. Chemed's return on equity of 26.04% beat Health Catalyst's return on equity of -20.06%.

Chemed has a consensus price target of $646.67, signalling upside risk potential of 43.29%. On the other hand Health Catalyst has an analysts' consensus of $6.89 which suggests that it could grow by 88.74%. Given that Health Catalyst has higher upside potential than Chemed, analysts believe Health Catalyst is more attractive than Chemed.

Chemed has a beta of 0.496, which suggesting that the stock is 50.426% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.024%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.44%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $646.9M, which are larger than Health Catalyst quarterly revenues of $79.4M. Chemed's net income of $71.8M is higher than Health Catalyst's net income of -$23.7M. Notably, Chemed's price-to-earnings ratio is 21.98x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 2.73x versus 0.73x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 11.09% compared to Chemed's net margin of 3.51%. Chemed's return on equity of 26.04% beat Option Care Health's return on equity of 15.22%.

Chemed has a consensus price target of $646.67, signalling upside risk potential of 43.29%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 30.79%. Given that Chemed has higher upside potential than Option Care Health, analysts believe Chemed is more attractive than Option Care Health.

Chemed has a beta of 0.496, which suggesting that the stock is 50.426% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.892%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.44%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $646.9M, which are smaller than Option Care Health quarterly revenues of $1.3B. Chemed's net income of $71.8M is higher than Option Care Health's net income of $46.7M. Notably, Chemed's price-to-earnings ratio is 21.98x while Option Care Health's PE ratio is 23.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 2.73x versus 0.97x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 11.09% compared to Chemed's net margin of -10.03%. Chemed's return on equity of 26.04% beat OptimizeRx's return on equity of -13.03%.

Chemed has a consensus price target of $646.67, signalling upside risk potential of 43.29%. On the other hand OptimizeRx has an analysts' consensus of $15.67 which suggests that it could grow by 20.79%. Given that Chemed has higher upside potential than OptimizeRx, analysts believe Chemed is more attractive than OptimizeRx.

Chemed has a beta of 0.496, which suggesting that the stock is 50.426% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.25%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.44%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $646.9M, which are larger than OptimizeRx quarterly revenues of $21.9M. Chemed's net income of $71.8M is higher than OptimizeRx's net income of -$2.2M. Notably, Chemed's price-to-earnings ratio is 21.98x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 2.73x versus 2.52x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.